Evidence map›Paper›PMID 37821954›Full record

ArticleJournal of experimental & clinical cancer research : CR2023

Tumor removal limits prostate cancer cell dissemination in bone and osteoblasts induce cancer cell dormancy through focal adhesion kinase.

Ruihua Liu, Shang Su, Jing Xing, Ke Liu, Yawei Zhao, Mary Stangis, Diego P Jacho, Eda D Yildirim-Ayan, Cara M Gatto-Weis, Bin Chen and 1 more

Open access · goldAbstract read
In one paragraph

Article in Journal of experimental & clinical cancer research : CR, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 20 papers.

0numbers the graph read from it
0cells of the map it votes in
20citing papers in PubMed
4.4field-weighted citation impact, top 5% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

20 citing papers in PubMed, 19 citations in OpenAlex.

  1. Review
  2. Article
  3. Review
  4. Article
  5. Review
  6. Review
  7. Review
  8. Article
  9. Unlocking Lung Cancer Cell Dormancy: An Epigenetic Perspective.International journal of molecular sciences · 2025
    Review
  10. Article
  11. Review
  12. Review
  13. Article
  14. Review
  15. Review
  16. Colorectal cancer and dormant metastases: Put to sleep or destroy?World journal of gastrointestinal oncology · 2024
    Article
  17. Review
  18. Review
  19. Review
  20. Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 2 institutions in 1 country.

Ruihua Liu *Department of Cell and Cancer Biology, College of Medicine and Life Sciences, the University of Toledo, 3000 Transverse Drive, Toledo, OH, 43614, USA.
Shang Su *Department of Cell and Cancer Biology, College of Medicine and Life Sciences, the University of Toledo, 3000 Transverse Drive, Toledo, OH, 43614, USA.
Jing Xing *Department of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, 49503, USA.
Ke LiuDepartment of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, 49503, USA.
Yawei ZhaoDepartment of Cell and Cancer Biology, College of Medicine and Life Sciences, the University of Toledo, 3000 Transverse Drive, Toledo, OH, 43614, USA.
Mary StangisDepartment of Cell and Cancer Biology, College of Medicine and Life Sciences, the University of Toledo, 3000 Transverse Drive, Toledo, OH, 43614, USA.
Diego P JachoBioengineering Department, the University of Toledo, Toledo, OH, 43606, USA.
Eda D Yildirim-AyanBioengineering Department, the University of Toledo, Toledo, OH, 43606, USA.
Cara M Gatto-WeisDepartment of Pathology, College of Medicine and Life Sciences, the University of Toledo, Toledo, OH, 43614, USA.
Bin ChenDepartment of Pediatrics and Human Development, College of Human Medicine, Michigan State University, Grand Rapids, MI, 49503, USA. chenbi12@msu.edu.
Xiaohong LiDepartment of Cell and Cancer Biology, College of Medicine and Life Sciences, the University of Toledo, 3000 Transverse Drive, Toledo, OH, 43614, USA. xiaohong.li@utoledo.edu.
University of Toledo · USMichigan State University · US

Funding

Repurpose open data to discover therapeutics for understudied diseasesR01GM134307 · NIGMS · MICHIGAN STATE UNIVERSITY · PI CHEN, BIN · 2019 to 2023
$2.5M
Influence of bone microenvironment on drug resistance in prostate cancer bone metastasisR01CA230744 · NCI · VAN ANDEL RESEARCH INSTITUTE · PI LI, XIAOHONG · 2019 to 2024
$1.9M
virtual compound screening using gene expressionR01GM145700 · NIGMS · MICHIGAN STATE UNIVERSITY · PI CHEN, BIN, ZHOU, JIAYU · 2022 to 2025
$1.9M
NCI NIH HHS NIH/NCI R01CA230744NCI NIH HHS R01 CA230744NIGMS NIH HHS NIH/NIGMS R01GM134307NIGMS NIH HHS NIH/NIGMS R01GM145700NIGMS NIH HHS R01 GM134307NIGMS NIH HHS R01 GM145700
6 · The paper itself

Abstract

backgroundDisseminated tumor cells (DTCs) can enter a dormant state and cause no symptoms in cancer patients. On the other hand, the dormant DTCs can reactivate and cause metastases progression and lethal relapses. In prostate cancer (PCa), relapse can happen after curative treatments such as primary tumor removal. The impact of surgical removal on PCa dissemination and dormancy remains elusive. Furthermore, as dormant DTCs are asymptomatic, dormancy-induction can be an operational cure for preventing metastases and relapse of PCa patients.

methodsWe used a PCa subcutaneous xenograft model and species-specific PCR to survey the DTCs in various organs at different time points of tumor growth and in response to tumor removal. We developed in vitro 2D and 3D co-culture models to recapitulate the dormant DTCs in the bone microenvironment. Proliferation assays, fluorescent cell cycle reporter, qRT-PCR, and Western Blot were used to characterize the dormancy phenotype. We performed RNA sequencing to determine the dormancy signature of PCa. A drug repurposing algorithm was applied to predict dormancy-inducing drugs and a top candidate was validated for the efficacy and the mechanism of dormancy induction.

resultsWe found DTCs in almost all mouse organs examined, including bones, at week 2 post-tumor cell injections. Surgical removal of the primary tumor reduced the overall DTC abundance, but the DTCs were enriched only in the bones. We found that osteoblasts, but not other cells of the bones, induced PCa cell dormancy. RNA-Seq revealed the suppression of mitochondrial-related biological processes in osteoblast-induced dormant PCa cells. Importantly, the mitochondrial-related biological processes were found up-regulated in both circulating tumor cells and bone metastases from PCa patients' data. We predicted and validated the dormancy-mimicking effect of PF-562,271 (PF-271), an inhibitor of focal adhesion kinase (FAK) in vitro. Decreased FAK phosphorylation and increased nuclear translocation were found in both co-cultured and PF-271-treated C4-2B cells, suggesting that FAK plays a key role in osteoblast-induced PCa dormancy.

conclusionsOur study provides the first insights into how primary tumor removal enriches PCa cell dissemination in the bones, defines a unique osteoblast-induced PCa dormancy signature, and identifies FAK as a PCa cell dormancy gatekeeper.

Indexed as

Neoplasm Recurrence, LocalProstatic NeoplasmsAnimalsCell Line, TumorFocal Adhesion Protein-Tyrosine KinasesHumansMaleMiceOsteoblastsRecurrenceTumor MicroenvironmentFocal Adhesion Protein-Tyrosine KinasesBone metastases; tumor removalDormancyFAKMitochondriaOsteoblastsProstate cancer

Identifiers

PMID37821954
PMCPMC10566127
OpenAlexW4387535872

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.